ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men
A drug used for breast and ovarian cancer is more effective than modern targeted hormone…
Browsing: ESMO 2019
ESMO 2019: New data from the TAILORx study on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years
A new analysis from TAILORx, the largest ever breast cancer treatment trial, has been published…
ESMO 2019: New studies question whether novel anti-cancer drugs are worth their extra cost
Many new anti-cancer medicines add little value for patients compared to standard treatment and are…